Stonepine Capital Management LLC Has $344,000 Holdings in Exagen Inc. $XGN

Key Points

• Stonepine Capital Management LLC reduced its stake in Exagen Inc. by 61.9%, selling 155,302 shares in the first quarter and now holds approximately 0.53% of the company valued at $344,000.
• Exagen's recent earnings report indicated an EPS of ($0.18), matching analysts' estimates, with revenue of $17.20 million for the quarter, surpassing estimates.
• Analysts have set a buy rating on Exagen with an average price target of $11.25, following positive ratings and price upgrades from multiple brokerages.

Stonepine Capital Management LLC lowered its position in shares of Exagen Inc. (NASDAQ:XGN - Free Report) by 61.9% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 95,747 shares of the company's stock after selling 155,302 shares during the quarter. Stonepine Capital Management LLC owned 0.53% of Exagen worth $344,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Northern Trust Corp grew its holdings in Exagen by 16.7% during the fourth quarter. Northern Trust Corp now owns 18,375 shares of the company's stock valued at $75,000 after purchasing an additional 2,630 shares during the period. Geode Capital Management LLC grew its holdings in Exagen by 11.9% during the fourth quarter. Geode Capital Management LLC now owns 98,057 shares of the company's stock valued at $402,000 after purchasing an additional 10,442 shares during the period. Huntleigh Advisors Inc. grew its holdings in Exagen by 16.8% during the first quarter. Huntleigh Advisors Inc. now owns 83,108 shares of the company's stock valued at $298,000 after purchasing an additional 11,939 shares during the period. Palumbo Wealth Management LLC grew its holdings in Exagen by 14.4% during the first quarter. Palumbo Wealth Management LLC now owns 99,205 shares of the company's stock valued at $356,000 after purchasing an additional 12,501 shares during the period. Finally, Marshall Wace LLP acquired a new position in Exagen during the fourth quarter valued at approximately $66,000. Institutional investors and hedge funds own 75.25% of the company's stock.

Wall Street Analyst Weigh In

XGN has been the subject of several research analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $10.00 price target on shares of Exagen in a report on Wednesday, July 30th. BTIG Research reiterated a "buy" rating on shares of Exagen in a report on Wednesday, May 7th. Craig Hallum initiated coverage on shares of Exagen in a report on Wednesday, July 23rd. They issued a "buy" rating and a $12.00 price target for the company. KeyCorp upgraded shares of Exagen from a "sector weight" rating to an "overweight" rating and set a $12.00 price target for the company in a report on Wednesday, July 30th. Finally, Canaccord Genuity Group upped their price target on shares of Exagen from $8.00 to $11.00 and gave the company a "buy" rating in a report on Wednesday, July 30th. Seven equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $11.25.

Exagen Stock Performance

NASDAQ XGN traded up $0.19 on Friday, hitting $9.93. 67,069 shares of the stock were exchanged, compared to its average volume of 230,957. The company has a debt-to-equity ratio of 1.06, a current ratio of 4.95 and a quick ratio of 4.95. The business's fifty day moving average is $8.08 and its 200 day moving average is $6.12. Exagen Inc. has a 52 week low of $2.38 and a 52 week high of $10.34. The company has a market capitalization of $218.35 million, a PE ratio of -11.15 and a beta of 1.61.

Exagen (NASDAQ:XGN - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.18). The firm had revenue of $17.20 million for the quarter, compared to analyst estimates of $16.25 million. Exagen had a negative net margin of 28.85% and a negative return on equity of 130.38%. Exagen has set its FY 2025 guidance at EPS. Research analysts anticipate that Exagen Inc. will post -0.88 EPS for the current fiscal year.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).